These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

905 related items for PubMed ID: 15566357

  • 1. High-dose melphalan with autologous stem cell transplantation after VAD induction chemotherapy for treatment of amyloid light chain amyloidosis: a single centre prospective phase II study.
    Perz JB, Schonland SO, Hundemer M, Kristen AV, Dengler TJ, Zeier M, Linke RP, Ho AD, Goldschmidt H.
    Br J Haematol; 2004 Dec; 127(5):543-51. PubMed ID: 15566357
    [Abstract] [Full Text] [Related]

  • 2. An overview of the use of high-dose melphalan with autologous stem cell transplantation for the treatment of AL amyloidosis.
    Sanchorawala V, Wright DG, Seldin DC, Dember LM, Finn K, Falk RH, Berk J, Quillen K, Skinner M.
    Bone Marrow Transplant; 2001 Oct; 28(7):637-42. PubMed ID: 11704785
    [Abstract] [Full Text] [Related]

  • 3. Cyclophosphamide plus dexamethasone is an efficient initial treatment before high-dose melphalan and autologous stem cell transplantation in patients with newly diagnosed multiple myeloma: results of a randomized comparison with vincristine, doxorubicin, and dexamethasone.
    Mellqvist UH, Lenhoff S, Johnsen HE, Hjorth M, Holmberg E, Juliusson G, Tangen JM, Westin J, Nordic Myeloma Study Group.
    Cancer; 2008 Jan 01; 112(1):129-35. PubMed ID: 17973267
    [Abstract] [Full Text] [Related]

  • 4. Double high-dose therapy for Hodgkin's disease with dose-intensive cyclophosphamide, etoposide, and cisplatin (DICEP) prior to high-dose melphalan and autologous stem cell transplantation.
    Stewart DA, Guo D, Glück S, Morris D, Chaudhry A, deMetz C, Klassen J, Brown CB, Russell JA.
    Bone Marrow Transplant; 2000 Aug 01; 26(4):383-8. PubMed ID: 10982284
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Induction therapy with vincristine, adriamycin, dexamethasone (VAD) and intermediate-dose melphalan (IDM) followed by autologous or allogeneic stem cell transplantation in newly diagnosed multiple myeloma.
    Lokhorst HM, Sonneveld P, Cornelissen JJ, Joosten P, van Marwijk Kooy M, Meinema J, Nieuwenhuis HK, van Oers MH, Richel DJ, Segeren CN, Veth G, Verdonck LF, Wijermans PW.
    Bone Marrow Transplant; 1999 Feb 01; 23(4):317-22. PubMed ID: 10100574
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Risk-adapted autologous stem cell transplantation with adjuvant dexamethasone +/- thalidomide for systemic light-chain amyloidosis: results of a phase II trial.
    Cohen AD, Zhou P, Chou J, Teruya-Feldstein J, Reich L, Hassoun H, Levine B, Filippa DA, Riedel E, Kewalramani T, Stubblefield MD, Fleisher M, Nimer S, Comenzo RL.
    Br J Haematol; 2007 Oct 01; 139(2):224-33. PubMed ID: 17897298
    [Abstract] [Full Text] [Related]

  • 10. Complete remission status before autologous stem cell transplantation is an important prognostic factor in patients with multiple myeloma undergoing upfront single autologous transplantation.
    Kim JS, Kim K, Cheong JW, Min YH, Suh C, Kim H, Jo DY, Ryoo HM, Yoon SS, Lee JH, Korean Multiple Myeloma Working Party.
    Biol Blood Marrow Transplant; 2009 Apr 01; 15(4):463-70. PubMed ID: 19285634
    [Abstract] [Full Text] [Related]

  • 11. Tandem cycles of high-dose melphalan and autologous stem cell transplantation increases the response rate in AL amyloidosis.
    Sanchorawala V, Wright DG, Quillen K, Finn KT, Dember LM, Berk JL, Doros G, Fisher C, Skinner M, Seldin DC.
    Bone Marrow Transplant; 2007 Sep 01; 40(6):557-62. PubMed ID: 17589534
    [Abstract] [Full Text] [Related]

  • 12. Extended follow up of high-dose melphalan and autologous stem cell transplantation after vincristine, doxorubicin, dexamethasone induction in amyloid light chain amyloidosis of the prospective phase II HOVON-41 study by the Dutch-Belgian Co-operative Trial Group for Hematology Oncology.
    Hazenberg BP, Croockewit A, van der Holt B, Zweegman S, Bos GM, Delforge M, Raymakers RA, Sonneveld P, Vellenga E, Wijermans PW, von dem Borne PA, van Oers MH, de Weerdt O, Spoelstra FM, Lokhorst HM, Dutch-Belgian Cooperative Trial Group for Hematology Oncology.
    Haematologica; 2015 May 01; 100(5):677-82. PubMed ID: 25661441
    [Abstract] [Full Text] [Related]

  • 13. Induction bortezomib in Al amyloidosis followed by high dose melphalan and autologous stem cell transplantation: a single institution retrospective study.
    Scott EC, Heitner SB, Dibb W, Meyers G, Smith SD, Abar F, Kovacsovics T, Perez-Avraham G, Stentz A, Frires R, Dibb J, Maziarz RT.
    Clin Lymphoma Myeloma Leuk; 2014 Oct 01; 14(5):424-430.e1. PubMed ID: 24650974
    [Abstract] [Full Text] [Related]

  • 14. Early intensification and autologous stem cell transplantation in patients with systemic AL amyloidosis: a single-centre experience.
    Frossard V, Ketterer N, Rosselet A, Meier P, Cairoli A, Duchosal MA, Kovacsovics T.
    Ann Hematol; 2009 Jul 01; 88(7):681-5. PubMed ID: 19066891
    [Abstract] [Full Text] [Related]

  • 15. Dose-escalated CHOP and tailored intensification with IFE according to early response and followed by BEAM/autologous stem-cell transplantation in poor-risk aggressive B-cell lymphoma: a prospective study from the GEL-TAMO Study Group.
    Arranz R, Conde E, Grande C, Mateos MV, Gandarillas M, Albo C, Lahuerta JJ, Fernández-Rañada JM, Hernández MT, Alonso N, García Vela JA, Garzón S, Rodríguez J, Caballero D, Grupo Español de Linfomas/Trasplante Autólogo de Médula Osea (GEL-TAMO).
    Eur J Haematol; 2008 Mar 01; 80(3):227-35. PubMed ID: 18088400
    [Abstract] [Full Text] [Related]

  • 16. Autologous transplantation for primary systemic AL amyloidosis is feasible outside a major amyloidosis referral centre: the Calgary BMT Program experience.
    Chow LQ, Bahlis N, Russell J, Chaudhry A, Morris D, Brown C, Stewart DA.
    Bone Marrow Transplant; 2005 Oct 01; 36(7):591-6. PubMed ID: 16062177
    [Abstract] [Full Text] [Related]

  • 17. Rapid reversal of nephrotic syndrome due to primary systemic AL amyloidosis after VAD and subsequent high-dose chemotherapy with autologous stem cell support.
    Sezer O, Schmid P, Shweigert M, Heider U, Eucker J, Harder H, Sinha P, Radtke H, Possinger K.
    Bone Marrow Transplant; 1999 May 01; 23(9):967-9. PubMed ID: 10338056
    [Abstract] [Full Text] [Related]

  • 18. High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis.
    Jaccard A, Moreau P, Leblond V, Leleu X, Benboubker L, Hermine O, Recher C, Asli B, Lioure B, Royer B, Jardin F, Bridoux F, Grosbois B, Jaubert J, Piette JC, Ronco P, Quet F, Cogne M, Fermand JP, Myélome Autogreffe (MAG) and Intergroupe Francophone du Myélome (IFM) Intergroup.
    N Engl J Med; 2007 Sep 13; 357(11):1083-93. PubMed ID: 17855669
    [Abstract] [Full Text] [Related]

  • 19. Impact of three courses of intensified CHOP prior to high-dose sequential therapy followed by autologous stem-cell transplantation as first-line treatment in poor-risk, aggressive non-hodgkin's lymphoma: comparative analysis of Dutch-Belgian Hemato-Oncology Cooperative Group Studies 27 and 40.
    van Imhoff GW, van der Holt B, Mackenzie MA, Van't Veer MB, Wijermans PW, Ossenkoppele GJ, Schouten HC, Sonneveld P, Steijaert MM, Kluin PM, Kluin-Nelemans HC, Verdonck LF, Dutch-Belgian Hemato-Oncology Cooperative Group.
    J Clin Oncol; 2005 Jun 01; 23(16):3793-801. PubMed ID: 15809447
    [Abstract] [Full Text] [Related]

  • 20. Heart transplantation in systemic (AL) amyloidosis: a retrospective study of eight French patients.
    Mignot A, Varnous S, Redonnet M, Jaccard A, Epailly E, Vermes E, Boissonnat P, Gandjbakhch I, Herpin D, Touchard G, Bridoux F.
    Arch Cardiovasc Dis; 2008 Sep 01; 101(9):523-32. PubMed ID: 19041836
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 46.